Clinical Trial Update: A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing docetaxel alone versus docetaxel plus PF-3512676 for advanced breast cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PF-3512676
• Taxotere (docetaxel)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 2 | Status: WITHDRAWN